Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.77 |
| ▸ | MAOA | P21397 | 4/20 | 0.76 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.65 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23189125 | 0.90 | MAOB (0.82) | MAOBMAOA | |
| SCHEMBL8697768 | 0.88 | MAOB (0.78) | MAOBNR4A2MAOASMPD1MEN1 | |
| SCHEMBL14189704 | 0.88 | MAOB (0.78) | MAOBNR4A2MAOASMPD1 | |
| SCHEMBL1436486 | 0.88 | MAOB (1.00) | MAOBNR4A2MAOANR1H4 | |
| SCHEMBL339009 | 0.87 | NR4A2 (1.00) | MAOBNR4A2SMPD1MEN1KMT2A | |
| SCHEMBL7908051 | 0.87 | SRD5A2 (0.85) | MAOBNR4A2SMPD1MEN1KMT2A | |
| SCHEMBL2450743 | 0.87 | MAOB (0.77) | MAOBNR4A2MAOASMPD1MEN1 | |
| SCHEMBL30207018 | 0.87 | NR4A2 (1.00) | MAOBNR4A2SMPD1MEN1KMT2A | |
| SCHEMBL12182449 | 0.86 | MAOB (1.00) | MAOBMAOASMPD1 | |
| SCHEMBL2498881 | 0.86 | MAOB (0.76) | MAOBNR4A2MAOASMPD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109305920-A | A kind of preparation method of high-purity injection stage bricalin | 海南利能康泰制药有限公司 | 2019-02-05 | — | — | CN | claimed |
| CN-108503554-A | A kind of synthetic method of bricalin | 南京倍特医药科技有限公司 | 2018-09-07 | — | — | CN | claimed |
| EP-0079168-B1 | PROCESS FOR MAKING 1-(3-BENZYLOXYPHENYL)-1,1-DIMETHYLHEPTANE AND INTERMEDIATES THEREFOR | PFIZER INC. (US) | 1984-08-22 | — | — | EP | claimed |
| EP-0079168-A1 | Process for making 1-(3-benzyloxyphenyl)-1,1-dimethylheptane and intermediates therefor | PFIZER INC. (US) | 1983-05-18 | — | — | EP | claimed |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2026-05-26 | — | — | US | disclosed |
| CN-122010912-A | Antiviral 1, 3-dioxoindene compounds | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-06-12 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | NOVARTIS AG (CH) | 2025-04-29 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118546054-A | Method for preparing alpha-deuterated ketone compound by photocatalysis and application thereof | 武汉大学 | 2024-08-27 | — | — | CN | disclosed |
| US-4263438-A | 3-[2,4-(Disubstituted)-phenyl]azacycloalkanones as analgesics | PFIZER INC. (US) | 1981-04-21 | — | — | US | disclosed |
| EP-0026298-A1 | Method for promoting growth and reducing fat in animals using phenylethanolamine derivatives | AMERICAN CYANAMID COMPANY (US) | 1981-04-08 | — | — | EP | disclosed |
| US-4235913-A | ANALGESICS, TRANQUILIZERS | PFIZER INC. (US) | 1980-11-25 | — | — | US | disclosed |
| US-4166180-A | 2-ARYLPIPERAZINE DERIVATIVES AND THE PREPARATION THEREOF | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1979-08-28 | — | — | US | disclosed |
| US-4165323-A | ANALGESICS, TRANQUILIZERS | PFIZER INC. (US) | 1979-08-21 | — | — | US | disclosed |
| US-4147872-A | 3-[2-Hydroxy-4-(substituted)-phenyl]azacycloalkanes and derivatives thereof as analgesic agents and intermediates therefor | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4118559-A | CNS AGENTS, ANALGESICS, TRANQUILIZERS | PFIZER INC. (US) | 1978-10-03 | — | — | US | disclosed |
| US-3985779-A | ANTIINFLAMMATORY AND ANALGESIC ACTIVITIES | EISAI CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | MAOB 958/4885NR4A2 35/4885MAOA 841/4885 |
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | MAOB 2196/4885NR4A2 2834/4885MAOA 2518/4885 |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | IRF3, EIF2AK2, ZC3HAV1 | MAOB 2196/4885NR4A2 2834/4885MAOA 2518/4885 |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | MAOB 3351/4885NR4A2 204/4885MAOA 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.